We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01047072
Recruitment Status : Withdrawn
First Posted : January 12, 2010
Last Update Posted : October 31, 2012
National Cancer Institute (NCI)
Information provided by:
Fred Hutchinson Cancer Center

Brief Summary:
The purpose of the study is to see how well reduced intensity conditioning followed by a stem cell transplant from a donor (allogeneic) works in treating patients with severe systemic sclerosis. In an allogeneic stem cell transplant procedure, stem cells are taken from a healthy donor and transplanted into the patient. Stem cells can be donated by a family member or an unrelated donor who is a complete tissue type match.

Condition or disease Intervention/treatment Phase
Systemic Scleroderma Drug: fludarabine phosphate Radiation: total-body irradiation Drug: tacrolimus Drug: mycophenolate mofetil Biological: rituximab Drug: cyclophosphamide Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation Procedure: peripheral blood stem cell transplantation Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Clinical Trial of Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis
Estimated Primary Completion Date : September 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Arm I (transplant)
Patients receive fludarabine IV on days -4 to -2. Patients undergo total-body irradiation on day 0. Patients then undergo peripheral blood stem cell transplantation on day 0. Patients receive GVHD prophylaxis comprising tacrolimus PO twice daily on days -3 to 180 and taper and mycophenolate mofetil PO three times daily on days 0-28 and then twice daily until day 180 and taper.
Drug: fludarabine phosphate
Given IV
Other Names:
  • 2-F-ara-AMP
  • Beneflur
  • Fludara

Radiation: total-body irradiation
Undergo total-body irradiation
Other Name: TBI

Drug: tacrolimus
Given orally
Other Names:
  • FK 506
  • Prograf

Drug: mycophenolate mofetil
Given orally
Other Names:
  • Cellcept
  • MMF

Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Undergo transplantation

Procedure: peripheral blood stem cell transplantation
Undergo transplantation
Other Names:
  • PBPC transplantation
  • PBSC transplantation
  • peripheral blood progenitor cell transplantation
  • transplantation, peripheral blood stem cell

Active Comparator: Arm II (nontransplant)
Patients receive mycophenolate mofetil PO twice daily for 16 months, rituximab IV on days 1 and 15 and then repeated at 6 months, and cyclophosphamide IV at 28-32 day intervals or orally once daily for 16 months.
Drug: mycophenolate mofetil
Given orally
Other Names:
  • Cellcept
  • MMF

Biological: rituximab
Given IV
Other Names:
  • IDEC-C2B8
  • IDEC-C2B8 monoclonal antibody
  • Mabthera
  • Rituxan

Drug: cyclophosphamide
Given orally
Other Names:
  • CPM
  • CTX
  • Cytoxan
  • Endoxan
  • Endoxana

Primary Outcome Measures :
  1. Event-free survival [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Event-free survival [ Time Frame: 5 years ]
  2. Overall survival [ Time Frame: 2 years ]
  3. Overall survival [ Time Frame: 5 years ]
  4. Time to progression [ Time Frame: 2 years ]
  5. Time to progression [ Time Frame: 5 years ]
  6. Incidence of initiation of any SSC disease-modifying therapy other than that specified in the protocol treatment arms [ Time Frame: Up to 5 years ]
  7. Incidence of definite and probable viral, fungal, and bacterial infections [ Time Frame: Up to 5 years ]
  8. Median time to engraftment as defined as having greater than or equal to 5% donor T cells in the peripheral blood (donor T cell chimerism) [ Time Frame: From date of transplant to time of engraftment ]
  9. Rate of primary graft failure [ Time Frame: Day 56 ]
  10. Rate of secondary graft failure [ Time Frame: 1 year ]
  11. Probability of acute and chronic GVHD [ Time Frame: Up to 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with severe SSc as defined by the American College of Rheumatology and at high-risk for a fatal outcome based on the following prognostic factors from groups 1-5:

    • Group 1: Patients with 1) both a. and b. below; and 2) at least one of c., d. or e:

      • a. Diffuse cutaneous scleroderma with skin score of >= 16 (modified Rodnan skin scale)
      • b. Duration of systemic sclerosis =< 5 years from the onset of first non-Raynaud's symptom
      • c. Presence of interstitial lung disease with FVC or DLCOcorr =< 70% of predicted and evidence of alveolitis (abnormal bronchoalveolar lavage [BAL] or high resolution chest computed tomography [CT] scan)
      • d. Left heart failure with left ventricular ejection Fraction (LVEF) < 50% or pericardial effusion (mild-moderate) or 2nd or 3rd Atrial-Ventricular (AV) block; Myocardial disease not secondary to SSc must be excluded by a cardiologist
      • e. History of SSc-related renal disease that is not active at the time of screening; History of scleroderma hypertensive renal crisis is included in this criterion
    • Group 2: Patients will have progressive pulmonary disease as the primary indication for transplant as defined by a decrease in the FVC or DLCO by 15 percent or greater in the previous 12-month period. In addition, patients may have either less skin involvement than group 1 (mRSS < 16) if they have a history of diffuse cutaneous disease and the FVC or DLCOcorr is < 70% or both FVC and DLCOcorr >= 70% if they have diffuse cutaneous disease (mRSS > 16) at screening for the study; Patients must also have evidence of alveolitis as defined by abnormal chest CT or BAL
    • Group 3: Have progressive active SSc after prior autologous HCT based on the presence of progressive pulmonary disease; This will be defined by a decrease in the FVC since prior autologous transplant by 10 percent or greater, or DLCO since prior autologous transplant by 15 percent or greater in addition to evidence of alveolitis as defined by chest CT changes or BAL; If patients had prior autologous HCT on the SCOT clinical trial, they must have failed based on the defined study endpoints and be approved by the protocol principal investigator (PI)
    • Group 4: Patients who meet group 1 inclusion criteria but have FVC or DLCO < 70% plus have had an adverse event to cyclophosphamide preventing its further use (i.e., hemorrhagic cystitis, leucopenia with WBC, 2000 or ANC < 1000 or platelet count < 100,000 and other adverse events)
    • Group 5: Diffuse scleroderma with disease duration =< 2 years since development of first sign of skin thickening plus modified Rodnan skin score >= 25 plus ESR > 25 mm/1st hour and/or Hb < 11 g/dL not explained by causes other than active scleroderma.
  2. Unless patients have a DLCOcorr less than 45%, patients must have failed either oral or intravenous cyclophosphamide regimen defined as:

    • IV cyclophosphamide administration for > 6 months or a total cumulative IV dose of 6 g/m^2, or
    • oral cyclophosphamide administration for > 6 months regardless of dose, or
    • combination of oral and IV cyclophosphamide for > 6 months independent of dose
  3. Patient must have a sibling who is a) HLA-identical and b) could serve as a donor of a peripheral blood stem cell graft to be placed on the transplant arm or an unrelated donor matched at HLA-A, B, C, DRB1 and DQB1. Patients without an HLA-identical sibling or an HLA-matched unrelated donor that meet the above criteria will be placed on the non-transplant arm


  • The donor must be an HLA-identical sibling of the patient or an HLA-matched unrelated donor.
  • If the donor has reached the age of assent, then they must have completed the local institutional review board (IRB) assent process.
  • Donor must consent to G-CSF administration and to leukapheresis for HSC collection.
  • Donor must have adequate veins for leukapheresis or agree to placement of central venous catheter (femoral, subclavian).
  • Age 12-75 years; Pediatric donors must be > 50 kg body weight.

Exclusion Criteria:

  • Eligible for the NIH-sponsored randomized clinical trial (SCOT)
  • Fertile men or women unwilling to use contraceptive techniques during and for 12 months or until immunosuppression is discontinued following transplantation
  • Evidence of ongoing active infection
  • Pregnancy
  • Subjects with pulmonary, cardiac, hepatic, or renal impairment that would limit their ability to receive therapy and compromise their survival. This includes but is not restricted to, subjects with any of the following:

    • Severe pulmonary dysfunction defined as:

      1. A hemoglobin corrected DLCOcorr < 30% or FVC < 40% of predicted; or
      2. O2 saturation < 92% at rest without supplemental oxygen; or
      3. PO2 < 70 mmHg or pCO2 > 50 mmHg without supplemental oxygen
    • Significant uncontrolled pulmonary hypertension defined as:

      1. Pulmonary artery peak systolic pressure > 45 mmHg by echocardiogram and mean pulmonary artery pressure by right heart catheterization exceeding 32 mmHg at rest or 42 mm Hg during exercise; or
      2. New York Heart Association (NYHA)/World Health Organization (WHO) classification for pulmonary hypertension, Class III or IV
    • Cardiac: Uncontrolled clinically significant arrhythmias; clinical evidence of significant cardiac disease (NYHA Class III or IV); LVEF < 40% by echocardiogram
    • Significant renal pathology, defined as:

      1. Estimated CrCl < 60 mL/min (using Cockcroft-Gault formula based on actual body weight) or serum creatinine > 2.0 mg/dL OR
      2. Active, untreated SSc renal crisis at the time of enrollment
    • Active hepatitis or liver biopsy evidence of cirrhosis or periportal fibrosis. Total bilirubin > 2.5 x the upper limit of normal (and not related to Gilbert's syndrome) and/or Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 4 x the upper limit of normal
    • Patients with poorly controlled hypertension
    • Patients whose life expectancy is severely limited by illness other than autoimmune disease
  • DONOR:

    • Identical twin of patient
    • Female donors who are pregnant (positive B-HCG) or breastfeeding
    • Infection with human immunodeficiency virus (HIV) or active viral hepatitis (B or C)
    • Known allergy to G-CSF
    • Current serious systemic illness
    • Uncontrolled bacterial, viral or fungal infection (currently taking medication and progression of clinical symptoms)
    • Donors receiving experimental therapy or investigational agents
    • Donors with cancer other than treated basal cell or carcinoma in situ of cervix; Cancer treated with curative intent > 2 years previous will be reviewed on a case-by-case basis by a Protocol Chair or Medical Monitor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01047072

Layout table for location information
United States, Washington
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: George Georges Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Layout table for additonal information
Responsible Party: Georges, George, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
ClinicalTrials.gov Identifier: NCT01047072    
Other Study ID Numbers: 2363.00
NCI-2012-00139 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
First Posted: January 12, 2010    Key Record Dates
Last Update Posted: October 31, 2012
Last Verified: October 2012
Keywords provided by Fred Hutchinson Cancer Center:
Scleroderma, systemic sclerosis, allogeneic hematopoietic stem cell transplantation
Additional relevant MeSH terms:
Layout table for MeSH terms
Scleroderma, Systemic
Scleroderma, Diffuse
Pathologic Processes
Connective Tissue Diseases
Skin Diseases
Mycophenolic Acid
Fludarabine phosphate
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antineoplastic Agents, Immunological
Antimetabolites, Antineoplastic
Calcineurin Inhibitors
Enzyme Inhibitors
Antibiotics, Antineoplastic
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents